New Risk • Jun 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. 공시 • Apr 01
AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion. AP Biosciences Inc has filed an IPO in the amount of TWD 1.2562 billion.
Security Name: Shares
Securities Offered: 11,420,000
Price\Range: TWD 110 공시 • Feb 26
AP Biosciences Inc, Annual General Meeting, May 20, 2026 AP Biosciences Inc, Annual General Meeting, May 20, 2026. Location: 1 floor no,508, sec.7 chung hsiao e. rd., nangang district, taipei city Taiwan Board Change • Dec 13
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Director Ya-Chi Chen was the last director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 29
AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual Meeting AP Biosciences announced the presentation of new preclinical data for its lead asset, AP402, at the 2025 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address treatment-resistant HER2-positive cancers through conditional T-cell engagement. Results Summary: Specificity for p95HER2: AP402 demonstrates high-affinity binding to p95HER2, confirming its selectivity for the truncated isoform over full-length HER2. T-cell Activation: In co-culture assays, AP402 promoted robust IFN-g secretion from T cells, with activity relating to p95HER2 expression on target cells. Compared to combination treatments with individual parent antibodies, AP402 showed synergistic T-cell activation. Activation Across Multiple Cell Lines: AP402 induced strong IFN-g responses in multiple p95HER2-expressing cancer cell lines (e.g., SK-OV-3), demonstrating its potential applicability across tumor types. Antibody-Dependent Cellular Cytotoxicity (ADCC): AP402 induced dose-dependent ADCC activity in p95HER2- expressing MDA-MB-231 cells using CD16-NK-92MI effector cells. Cytotoxicity levels were positively related with p95HER2 expression. Pharmacokinetics and Toxicology in Non-Human Primates (NHPs): In cynomolgus monkeys, AP402 demonstrated a favorable pharmacokinetic profile and was well tolerated up to 100 mg/kg with no observed adverse effects at the highest dose. All findings reversed during the recovery phase. In conclusion, the preclinical data show that AP402 effectively engages innate and adaptive immune responses, demonstrates robust antitumor activity in p95HER2 -expressing tumor models, and is well tolerated in non-human primates. These findings support the continued development of AP402, which recently entered clinical evaluation in Australia (NCT06669975). AP402 is a first-in-class bispecific antibody developed by AP Biosciences to target p95HER2, a truncated variant of HER2 associated with resistance to Herceptin and poorer prognosis. This variant is present in approximately 30-40% of HER2-positive breast cancer patients. By leveraging p95HER2 recognition to cluster CD137, the design enables localized T-cell activation within the tumor microenvironment, helping to minimize systemic cytokine-related toxicity. The binding domains for p95HER2 and CD 137 are strategically positioned on oppositeends to enhance bridging between HER2 variant-expressing cancer cells and CD137-expressing T-cells, ensuring efficient immune cell recruitment without spatial hindrance. This novel mechanism has positioned AP402 as a promising therapeutic approach to addressing tumors that have developed resistance to traditional anti-HER2 therapies, offering potential new hope for patients with refractory/recurrent cancers. 공시 • Apr 23
AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients AP Biosciences announced that it has dosed the first patient in its Phase 1 study evaluating AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2 in patients relapsed/refractory to anti-HER2 treatment. The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors, including breast cancer. The following dose expansion phase of the study may include clinical sites in Taiwan, South Korea and the United States. AP402-101 (NCT06669975), is a multi-center, open-label Phase 1 trial, enrolling up to 85 patients divided in two parts: a dose-escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), followed by a dose-expansion phase targeting specific HER2-positive tumor types. Primary endpoints of the study include safety and tolerability, while secondary endpoints will evaluate objective response rate (ORR), disease control rate (DCR), and pharmacokinetic (PK) parameters. Exploratory endpoints will assess pharmacodynamic biomarkers and immunogenicity. 